OSCOTECInc오스코텍

Oscotec's recent profits come mainly from a one-off-style licensing windfall, while the share price sits well below its 52-week high.

Oscotec, a Korean drug discovery firm, reported trailing twelve-month revenue of ₩144.2B and operating income of ₩89.7B through H1 2026, far above its earlier loss-making years. Most of its revenue in its latest year came from technology transfer and royalty income tied to a lung cancer drug licensed to a Korean pharmaceutical firm. The shares closed at ₩36,000 on 2026-10-26, down 5% over one year and about 45% below the 52-week high of ₩66,000.

What stands out

• Revenue jumped from ₩34.0B in 2024 to ₩99.8B in 2025, and trailing figures show ₩144.2B, but the company lost money in every year from 2021 to 2023.
• Trailing operating margin is 62.2% and net margin 65.2%, which is unusually high and relies on licensing income rather than steady product sales.
• Trailing free cash flow is ₩90.6B against cash of ₩32.4B and borrowings of ₩11.5B, so liabilities are modest relative to equity (19.2%).
• Valuation shows P/E of 14.6 and P/B of 6.4, with a market cap of about ₩1.38T; the data gives no analyst ratings or price targets.
• Recent filings include a shareholders' meeting call, a record date notice, a lawsuit filing or ruling, and several 5%+ holding reports, while a news item covered a website revamp.

What to watch

• The shareholders' meeting and record date notices filed in October 2026, including any agenda items the filings set out.
• The lawsuit recorded in late September 2026; the data does not say what it concerns or its likely outcome.
• Whether licensing and royalty income continues at a similar level, since the trailing profit depends heavily on it; the data does not show future contract terms.